Dyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at Raymond James

Raymond James assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a research note issued to investors on Wednesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $37.00 target price on the stock.

A number of other research analysts have also issued reports on the stock. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Piper Sandler dropped their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Oppenheimer initiated coverage on shares of Dyne Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $44.93.

Dyne Therapeutics Trading Down 1.4%

Dyne Therapeutics stock traded down $0.21 during mid-day trading on Wednesday, reaching $14.26. The company had a trading volume of 58,596 shares, compared to its average volume of 1,673,044. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a market cap of $1.62 billion, a P/E ratio of -4.04 and a beta of 1.17. The business has a fifty day simple moving average of $11.04 and a 200 day simple moving average of $15.33.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of DYN. Caitong International Asset Management Co. Ltd increased its holdings in shares of Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after acquiring an additional 2,446 shares in the last quarter. Quarry LP acquired a new stake in shares of Dyne Therapeutics in the 1st quarter worth about $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $50,000. E Fund Management Co. Ltd. lifted its position in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Optimize Financial Inc acquired a new position in Dyne Therapeutics during the 1st quarter valued at about $154,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.